NanJing Pharmaceutical Company Limited

SSE:600713.SS

5.19 (CNY) • At close June 6, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993
Revenue 53,696.17453,589.66550,221.56445,123.19539,817.36437,155.74231,303.04627,473.44926,720.50124,813.08722,075.78118,737.7918,024.2217,171.69415,337.62714,025.51411,396.2889,344.8586,827.7046,229.6855,259.7184,217.4252,068.691,428.6441,329.2011,146.28879.497582.339502.805489.879406.031454.988
Cost of Revenue 50,323.07850,282.6146,962.4342,185.98537,286.1534,698.9229,235.11725,734.52325,149.00723,344.12120,738.03517,543.50316,660.83915,962.52714,248.33913,111.00210,564.2068,656.1166,349.7715,777.7174,830.1753,798.521,805.0521,198.1981,110.04959.433715.01459.57412.18405.867338.711394.784
Gross Profit 3,373.0963,307.0553,259.1342,937.212,531.2142,456.8232,067.9291,738.9261,571.4941,468.9671,337.7461,194.2881,363.3811,209.1671,089.288914.513832.082688.742477.933451.968429.543418.905263.638230.446219.16186.847164.487122.76990.62584.01267.3260.204
Gross Profit Ratio 0.0630.0620.0650.0650.0640.0660.0660.0630.0590.0590.0610.0640.0760.070.0710.0650.0730.0740.070.0730.0820.0990.1270.1610.1650.1630.1870.2110.180.1710.1660.132
Reseach & Development Expenses 30.63536.18927.43420.95815.99913.3516.4341.76.0481.7170000000000000000000000
General & Administrative Expenses 127.138135.30177.51953.66754.260.10462.69355.66965.01258.468108.135118.914186.204182.357136.783322.804296.517262.535245.488239.369229.157196.243131.566107.27186.97651.67957.88843.30736.29530.10722.66710.542
Selling & Marketing Expenses 461.495459.5271,157.5841,076.071953.444976.561824.149692.216575.341516.507474.928476.545562.582549.289458.165401.373369.493282.539181.426166.01160.205150.581.45486.93172.07548.23131.81429.78717.33413.73112.40211.966
SG&A 588.6321,674.4851,235.1031,129.7381,007.6441,036.664886.842747.886640.353574.975583.064595.459748.786731.646594.948724.177666.01545.074426.914405.379389.362346.743213.02194.203159.05199.9189.70273.09453.62943.83835.06922.508
Other Expenses 1,730.425588.938497.323455.161389.277402.387-3.936-20.926-6.76215.61325.73120.54198.82613.848.54434.84812.99927.14541.05825.04717.458.7273.3614.2623.4711.4470.2092.7694.494-0.059-0.7850.012
Operating Expenses 2,349.6922,299.6121,759.861,605.8571,412.9191,452.4031,260.5551,053.209981.209946.55900.135908.2921,085.7591,094.588884.726743.127682.119557.272435.741413.645396.794354.282218.744198.657163.487103.75893.12175.38755.50446.10535.67229.874
Operating Income 1,023.4041,007.4431,320.051,233.9221,037.2331,068.734479.732460.908346.847258.995180.486107.498-40.083-162.206-11.78259.45851.82596.3418.77429.57116.8548.56947.39955.90767.69990.91773.18645.61932.22226.72221.25811.551
Operating Income Ratio 0.0190.0190.0260.0270.0260.0290.0150.0170.0130.010.0080.006-0.002-0.009-0.0010.0040.0050.010.0030.0050.0030.0120.0230.0390.0510.0790.0830.0780.0640.0550.0520.025
Total Other Income Expenses Net -20.009-29.375-413.519-6.8471.53860.147-3.936-56.084-7.17612.10823.53913.448-219.801-182.443-124.04533.546-85.40927.14516.0077.314.4842.4-1.597-1.292-6.512-1.584-1.022-0.6963.294-0.643-0.7850.012
Income Before Tax 1,003.395978.068906.012838.866677.799588.87475.796439.982339.786271.103204.025121.23557.821-149.9936.17393.99864.555123.48535.01436.8821.33550.96945.80254.61466.09988.50372.16444.92435.51626.07920.47411.563
Income Before Tax Ratio 0.0190.0180.0180.0190.0170.0160.0150.0160.0130.0110.0090.0060.003-0.0090.0020.0070.0060.0130.0050.0060.0040.0120.0220.0380.050.0770.0820.0770.0710.0530.050.025
Income Tax Expense 260.275265.259190.092228.314207.761157.32129.964128.73101.19278.41651.61161.41662.99233.47442.49239.01920.40152.14310.7369.4439.70415.8939.98413.66513.10512.80911.7256.8165.2948.8226.8033.3
Net Income 570.628577.826595.668505.183376.413346.92264.294239.271180.272156.724128.8838.68110.82-182.6179.37446.24230.33546.6818.58418.3542.40220.53828.19836.89848.52774.01559.41438.10730.22217.25713.6718.263
Net Income Ratio 0.0110.0110.0120.0110.0090.0090.0080.0090.0070.0060.0060.0020.001-0.0110.0010.0030.0030.0050.0030.00300.0050.0140.0260.0370.0650.0680.0650.060.0350.0340.018
EPS 0.440.450.480.490.360.330.260.260.20.180.180.0560.016-0.260.0140.0820.0610.0780.0180.0390.0050.0440.0610.0720.0850.160.120.110.0840.0420.0340.02
EPS Diluted 0.440.450.480.490.360.330.260.260.20.180.180.0560.016-0.260.0140.0820.0610.0780.0180.0390.0050.0440.0610.0720.0850.160.120.110.0840.0420.0340.02
EBITDA 1,591.4121,619.3291,622.9421,548.0111,165.8361,193.678966.502753.886641.05362.545593.576472.877486.126246.602291.996284.458251.744260.914138.3132.164103.466119.85684.24980.72390.68295.56978.28547.38235.12137.90731.64830.33
EBITDA Ratio 0.030.030.0320.0340.0290.0320.0310.0270.0240.0150.0270.0250.0270.0140.0190.020.0220.0280.020.0210.020.0280.0410.0570.0680.0830.0890.0810.070.0770.0780.067